Axsome Q3: Revenue Up 52% to $259.7M, Net Loss Narrows to $12.9M
AXSM is trading near its 52-week low of $123 (12% above the low) on elevated volume (3.3× avg).
Summary
Axsome grew Q3 revenue 52% to $259.7 million and cut its net loss to $12.9 million, with $313.9 million of cash and the $70 million revolver repaid in October.
Key Events · Earnings and Guidance · AXSM
-
Q3 Revenue Jumps 52%
Total revenues were $259.7 million versus $171.0 million a year earlier; AUVELITY contributed $207.6 million and SUNOSI $38.5 million.
-
Net Loss Narrows Sharply
Net loss fell to $12.9 million, or $0.25 per share, from $47.2 million, or $0.94 per share, in Q3 2025.
-
Cash Covers Twelve Months
Cash and equivalents stood at $313.9 million at September 30, 2026, which management says funds anticipated operating requirements for at least twelve months.
-
Revolver Repaid in October
The $70.0 million Blackstone revolver balance at quarter end was repaid in full in October 2026, leaving $20.0 million undrawn at September 30.
Analysis · AXSM · Life Sciences
The commercial model is scaling: total revenue reached $259.7 million versus $171.0 million a year ago, with AUVELITY alone at $207.6 million as the Alzheimer's-agitation launch adds volume. Net loss shrank to $12.9 million from $47.2 million, and the company ended September with $313.9 million in cash—enough, management says, to cover at least twelve months of operations. Two balance-sheet items matter for risk: the $70 million revolver was repaid in full in October, and the long-running stockholder derivative suit was dismissed with prejudice on October 13, 2026. The offset is spending—SG&A rose to $203.1 million from $150.2 million on the ADA launch, direct-to-consumer advertising and sales-force expansion—so profitability still depends on holding that revenue growth.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXSM was trading at $137.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $123.00 to $260.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.